Company research
Gossamer Bio, Inc.
CIK 1728117Updated Nov 11, 2026
SecurityGOSS · NASDAQ · equity
GOSS price & chart
Loading TradingView…
NASDAQ:GOSS on TradingView ↗About the company
Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
In the news
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm ↗
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS ↗
GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 208,820,000Source | 350,879,000Source | 76,867,000Source | 240,925,000Source | 373,448,000Source | 128,899,000Source | 280,589,000Source | 259,360,000Source | 172,249,000Source | 315,292,000Source | 311,916,000Source | 272,450,000Source |
| Property, Plant and Equipment, NetUSD | 70,000Source | 302,000Source | 55,000Source | 76,000Source | 824,000Source | 59,000Source | 29,000Source | 1,074,000Source | 64,000Source | 10,000Source | 1,648,000Source | 3,981,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,933,000Source | 28,464,000Source | 41,148,000Source | 26,309,000Source | 86,877,000Source | 41,028,000Source | 29,021,000Source | 38,863,000Source | 37,732,000Source | 46,074,000Source | 32,109,000Source | 111,973,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,243,000Source | 6,588,000Source | 6,105,000Source | 7,579,000Source | 3,629,000Source | 9,252,000Source | 6,583,000Source | — | 12,227,000Source | 5,338,000Source | — | — |
| Assets, CurrentUSD | 203,989,000Source | 344,268,000Source | 72,725,000Source | 235,898,000Source | 370,903,000Source | 124,536,000Source | 275,475,000Source | 255,269,000Source | 167,644,000Source | 309,888,000Source | 306,519,000Source | 261,880,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 14,522,000Source | 10,646,000Source | 9,594,000Source | 15,401,000Source | 12,786,000Source | 16,069,000Source | 10,958,000Source | 10,875,000Source | 18,485,000Source | 10,032,000Source | 10,094,000Source | 6,202,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,354,000Source | 6,026,000Source | 3,658,000Source | 4,568,000Source | 1,662,000Source | 3,906,000Source | 4,775,000Source | 2,404,000Source | 4,133,000Source | 5,111,000Source | 3,131,000Source | 5,909,000Source |
| Other Assets, NoncurrentUSD | 407,000Source | 283,000Source | 429,000Source | 383,000Source | 59,000Source | 398,000Source | 310,000Source | 613,000Source | 408,000Source | 283,000Source | 618,000Source | 680,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 291,153,000Source | 296,743,000Source | 170,896,000Source | 287,032,000Source | 291,919,000Source | 290,382,000Source | 286,839,000Source | 232,638,000Source | 295,009,000Source | 285,800,000Source | 249,147,000Source | 260,373,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 24,000Source | 23,000Source | 50,000Source | 23,000Source | 23,000Source | 24,000Source | 23,000Source | 23,000Source | 24,000Source | 23,000Source | 23,000Source | 10,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,391,700,000Source | -1,235,539,000Source | -1,468,702,000Source | -1,343,479,000Source | -1,204,736,000Source | -1,485,602,000Source | -1,305,206,000Source | -1,253,968,000Source | -1,438,938,000Source | -1,268,568,000Source | -1,212,040,000Source | -1,032,223,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -5,107,000Source | -2,231,000Source | -3,734,000Source | -5,088,000Source | -518,000Source | -4,024,000Source | -824,000Source | -628,000Source | -5,149,000Source | 1,189,000Source | -350,000Source | -574,000Source |
| Stockholders' Equity Attributable to ParentUSD | -82,333,000Source | 54,136,000Source | -94,029,000Source | -46,107,000Source | 81,529,000Source | -161,483,000Source | -6,250,000Source | 26,722,000Source | -122,760,000Source | 29,492,000Source | 62,769,000Source | 12,077,000Source |
| Additional Paid in Capital, Common StockUSD | 1,314,450,000Source | 1,291,883,000Source | 1,378,357,000Source | 1,302,437,000Source | 1,286,760,000Source | 1,328,119,000Source | 1,299,757,000Source | 1,281,295,000Source | 1,321,303,000Source | 1,296,848,000Source | 1,275,136,000Source | 1,044,864,000Source |
| Liabilities and EquityUSD | 208,820,000Source | 350,879,000Source | 76,867,000Source | 240,925,000Source | 373,448,000Source | 128,899,000Source | 280,589,000Source | 259,360,000Source | 172,249,000Source | 315,292,000Source | 311,916,000Source | 272,450,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 62,117,000Source | 51,085,000Source | 137,783,000Source | 53,594,000Source | 45,185,000Source | 56,506,000Source | 48,223,000Source | 35,819,000Source | 63,435,000Source | 45,010,000Source | 51,598,000Source | 49,230,000Source |
| Operating Lease, Liability, CurrentUSD | 919,000Source | 1,748,000Source | 965,000Source | 890,000Source | 1,826,000Source | 957,000Source | 853,000Source | 2,645,000Source | 938,000Source | 961,000Source | 3,302,000Source | 2,983,000Source |
| Accounts Payable, CurrentUSD | 1,116,000Source | 3,057,000Source | 5,951,000Source | 1,876,000Source | 1,000,000Source | 10,822,000Source | 3,389,000Source | 2,660,000Source | 5,959,000Source | 2,319,000Source | 5,526,000Source | 1,459,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,700,000Source | 4,593,000Source | 2,958,000Source | 3,934,000Source | 0Source | 3,213,000Source | 4,170,000Source | 0Source | 3,460,000Source | 4,398,000Source | 144,000Source | 3,446,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 19,291,000Source | 17,423,000Source | 17,710,000Source | 12,645,000Source | 16,311,000Source | 19,548,000Source | 12,224,000Source | 14,641,000Source | 15,827,000Source | 15,186,000Source | 26,680,000Source | 20,532,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 0Source | — | — | 0Source | — | — | 9,589,000Source | — | 0Source | 11,613,000Source | 11,613,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 814,000Source | 11,988,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -46,664,000Source | -36,638,000Source | -170,370,000Source | -56,528,000Source | -179,817,000Source | -229,378,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 5,000Source | 6,000Source | 24,000Source | 833,000Source | 1,607,000Source | 1,832,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 6,304,000Source | 2,405,000Source | 10,555,000Source | 20,619,000Source | 28,518,000Source | 42,553,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 6,156,000Source | -937,000Source | -2,747,000Source | -1,656,000Source | 3,990,000Source | -1,813,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -38,721,000Source | -39,724,000Source | -171,266,000Source | -3,468,000Source | -159,158,000Source | -187,032,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 41,606,000Source | 22,062,000Source | 156,358,000Source | 29,023,000Source | -110,970,000Source | -1,035,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 26,000Source | 79,000Source | 0Source | 0Source | 410,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 512,000Source | 504,000Source | 6,425,000Source | -11,488,000Source | 190,154,000Source | 117,090,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | 0Source | 0Source | 12,581,000Source | 11,613,000Source | 5,806,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 3,296,000Source | -17,053,000Source | -8,342,000Source | 13,965,000Source | -79,864,000Source | -71,494,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 8,933,000Source | 28,464,000Source | 41,148,000Source | 26,309,000Source | 41,028,000Source | 29,021,000Source | 37,732,000Source | 46,074,000Source | 32,109,000Source | 111,973,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 10,000,000Source | 10,561,000Source | 12,288,000Source | 12,712,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,666,000Source | 4,842,000Source | 2,463,000Source | 2,586,000Source | 6,304,000Source | 2,405,000Source | 10,555,000Source | 20,619,000Source | 28,518,000Source | 42,553,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 255,000Source | 241,000Source | 985,000Source | 1,086,000Source | 1,321,000Source | 1,163,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 0Source | 800,000Source | 1,600,000Source | 1,800,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | -806,000Source | -726,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 9,390,000Source | 8,502,000Source | 8,900,000Source | 8,679,000Source | 18,746,000Source | 8,658,000Source | 37,631,000Source | 36,133,000Source | 38,455,000Source | 47,609,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -1,132,000Source | — | 0Source | — | — | -88,000Source | 893,000Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 2,748,000Source | 2,734,000Source | 2,705,000Source | 2,744,000Source | 2,755,000Source | 2,746,000Source | 10,989,000Source | 11,517,000Source | — | — |
| Investment Income, InterestUSD | — | — | 687,000Source | 430,000Source | 268,000Source | 542,000Source | 354,000Source | 294,000Source | 1,970,000Source | 1,779,000Source | 1,997,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -48,221,000Source | -30,803,000Source | 16,900,000Source | -38,273,000Source | -46,664,000Source | -36,638,000Source | -170,370,000Source | -56,528,000Source | -179,817,000Source | -229,378,000Source |
| Nonoperating Income (Expense)USD | — | — | 893,000Source | 1,984,000Source | 42,974,000Source | 492,000Source | -1,798,000Source | 172,000Source | 270,000Source | 4,284,000Source | 3,942,000Source | — |
| Operating ExpensesUSD | — | — | 62,408,000Source | 43,399,000Source | 35,312,000Source | 50,254,000Source | 61,821,000Source | 46,699,000Source | 219,199,000Source | 174,620,000Source | 183,759,000Source | 218,593,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,100,000Source | — | — | — | — | — | — | 3,400,000Source | 3,300,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,954,000Source | 4,288,000Source | -4,150,000Source | 2,694,000Source | 603,000Source | 2,624,000Source | 9,289,000Source | 14,022,000Source | 15,456,000Source | 1,512,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 220,000Source | 132,000Source | 1,930,000Source | 0Source | 0Source | 1,736,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | 5,000Source | — | — | 0Source |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 13,294,000Source | 9,480,000Source | 9,238,000Source | 11,489,000Source | 16,955,000Source | 9,889,000Source | 48,471,000Source | 114,701,000Source | — | — |
| Operating Income (Loss)USD | — | — | -49,114,000Source | -33,919,000Source | -26,074,000Source | -38,765,000Source | -44,866,000Source | -36,810,000Source | -170,728,000Source | -59,919,000Source | -183,759,000Source | -218,593,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,954,000Source | 4,288,000Source | -4,150,000Source | 2,694,000Source | 603,000Source | 2,624,000Source | 9,289,000Source | 14,022,000Source | 15,456,000Source | 1,512,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -48,221,000Source | -31,935,000Source | — | -38,273,000Source | — | — | -170,458,000Source | -55,635,000Source | -179,809,000Source | -229,370,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -1,132,000Source | — | 0Source | — | — | -88,000Source | 893,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -48,221,000Source | -30,803,000Source | 16,900,000Source | -38,273,000Source | -46,664,000Source | -36,638,000Source | -170,370,000Source | -56,528,000Source | -179,817,000Source | -229,378,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.21Source | -0.14Source | 0.05Source | -0.17Source | -0.2Source | -0.16Source | -0.75Source | -0.25Source | -1.18Source | -2.71Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.21Source | -0.14Source | -0.08Source | -0.17Source | -0.2Source | -0.16Source | -0.75Source | -0.25Source | -1.18Source | -2.71Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 227,981,475Source | 226,346,058Source | 320,014,255Source | 227,275,466Source | 234,137,364Source | 226,818,051Source | 228,519,130Source | 226,228,016Source | 152,621,669Source | 84,574,869Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 227,981,475Source | 226,346,058Source | 328,776,495Source | 227,275,466Source | 234,137,364Source | 226,818,051Source | 228,519,130Source | 226,228,016Source | 152,621,669Source | 84,574,869Source |
| Interest Expense (non-operating)USD | — | — | 2,748,000Source | 2,734,000Source | 2,705,000Source | 2,744,000Source | 2,755,000Source | 2,746,000Source | 10,989,000Source | 11,517,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 9,390,000Source | 8,502,000Source | 8,900,000Source | 8,679,000Source | 18,746,000Source | 8,658,000Source | 37,631,000Source | 36,133,000Source | 38,455,000Source | 47,609,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -138,048,000Source | -32,178,000Source | -134,073,000Source | -175,777,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 13,511,000Source | 13,880,000Source |
| Investment Income, InterestUSD | — | — | 687,000Source | 430,000Source | 268,000Source | 542,000Source | 354,000Source | 294,000Source | 1,970,000Source | 1,779,000Source | 1,997,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 893,000Source | 1,984,000Source | 42,974,000Source | 492,000Source | -1,798,000Source | 172,000Source | 270,000Source | 4,284,000Source | 3,942,000Source | — |
| Operating ExpensesUSD | — | — | 62,408,000Source | 43,399,000Source | 35,312,000Source | 50,254,000Source | 61,821,000Source | 46,699,000Source | 219,199,000Source | 174,620,000Source | 183,759,000Source | 218,593,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,100,000Source | — | — | — | — | — | — | 3,400,000Source | 3,300,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | 5,000Source | — | — | 0Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-293009
Filing attachments
ex99-1.htm · SCHEDULE 13G/A · 2026-11-06
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 6, 2026, is by and among Opaleye Management Inc., Opaleye, L.P. and James Silverman (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G with respect to shares of common stock of Gossamer Bio, Inc. beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13d-1(k) …
Read attachment ↗tm2628588d1_ex99-1.htm · SCHEDULE 13D/A · 2026-10-29
SCHEDULE I Transactions in the Securities of the Issuer Since Amendment No. 5 Name Date Price per Common Number of Common Shares Share1 Purchased/(Sold) ────────────────────────────────────────────────────────────────────────────── Cogence 10/9/2026 9.672 (200) Valence 10/9/2026 9.663 (2,200) Cogence 10/12/2026 …
Read attachment ↗tm2628588d1_ex99-2.htm · SCHEDULE 13D/A · 2026-10-29
Exhibit 2 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. Shaw, hereby make, constitute, and appoint each of Adam Deaton, Anne Dinning, Edward Fishman, Alexis Halaby, Edwin Jager, Martin Lebwohl, Daniel Marcus, Anoop Prasad, Maximilian Stone, and David Sweet, acting individually in such person’s capacity as an employee of D. E. Shaw & Co., L.P. or one of its s…
Read attachment ↗tm2627334d1_ex99-1.htm · SCHEDULE 13D/A · 2026-10-08
SCHEDULE I Transactions in the Securities of the Issuer Since Amendment No. 4 Name Date Price per Common Share1 Number of Common Shares Purchased/(Sold) ───────────────────────────────────────────────────────────────────────────────────────────────────── Cogence 9/29/2026 11.622 (200) Valence 9/29/2026 11.573 (3,400) Cogence 9/…
Read attachment ↗tm2627334d1_ex99-2.htm · SCHEDULE 13D/A · 2026-10-08
Exhibit 2 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. Shaw, hereby make, constitute, and appoint each of Adam Deaton, Anne Dinning, Edward Fishman, Alexis Halaby, Edwin Jager, Martin Lebwohl, Daniel Marcus, Anoop Prasad, Maximilian Stone, and David Sweet, acting individually in such person’s capacity as an employee of D. E. Shaw & Co., L.P. or one of its s…
Read attachment ↗tm2626520d1_ex99-1.htm · SCHEDULE 13D/A · 2026-09-28
SCHEDULE I Transactions in the Securities of the Issuer Since Amendment No. 3 Name Date Price per Common Share1 Number of Common Shares Purchased/(Sold) ───────────────────────────────────────────────────────────────────────────────────────────────────── Cogence 8/25/2026 0.19872 (21,500) Valence 8/25/2026 0.19863 (415,800) Cogence 8/…
Read attachment ↗